UK markets open in 2 hours 1 minute

Oncternal Therapeutics, Inc. (GTU.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.0000-6.5200 (-100.00%)
At close: 09:00AM CEST
Full screen
Loading interactive chart…
  • GlobeNewswire

    Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

    Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the latter part of the second quarterPhase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for patients with relapsed or refractory aggressive B-cell lymphoma, including patients th

  • GlobeNewswire

    Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2024 financial results after the U.S. financial markets close on Thursday, May 9, 2024. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s financial results. The live webcast of the ca

  • GlobeNewswire

    Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management. The award will be made on May 1, 2024 under Oncternal’s 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity award